Vanda Pharmaceuticals | VNDA - Debt


Vanda Pharmaceuticals reported $4.96M in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 983.69M 5.77M Jun/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 725.8M 1.82M Jun/2026
J&J USD 54.99B 7.05B Mar/2026
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
Ligand Pharmaceuticals USD 451.98M 486K Mar/2026
Merck USD 49.12B 222M Mar/2026
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 1.3B 7M Mar/2026
Novartis USD 47B 14.98B Mar/2026
Pfizer USD 63.19B 536M Jun/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 23.58B 3.56B Jun/2026
Takeda JPY 4.94T 58.13B Jun/2026
Teva Pharmaceutical Industries USD 16.91B 187M Mar/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024
Veracyte USD 39.33M 321K Mar/2026